Primary and secondary prevention of cervical cancer

References

• Bosch FX, Lorincz A, Muñoz N et al. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol.55(4), 244–265 (2002).
   PubMed Web of Science ®Google Scholar
• WHO. IARC monographs on the evaluation of carcinogenic risks to humans. human papillomaviruses. WHO Press90, 1–689 (2007).
   Google Scholar
• Basu P, Sarkar S, Mukherjee S et al. Women’s perceptions and social barriers determine compliance to cervical screening: results from a population based study in India. Cancer Detect. Prev.30(4), 369–374 (2006).
   PubMedGoogle Scholar
• Stark A, Gregoire L, Pilarski R et al.Human papillomavirus, cervical cancer and women’s knowledge. Cancer Detect Prev.32(1), 15–22 (2008).
   PubMedGoogle Scholar
• IARC Working Group on the Evaluation of Cancer Preventive Strategies. Cervix cancer screening. In: IARC Handbooks of Cancer Prevention. (Volume 10). IARC Press, Lyon, France (2005).
   Google Scholar
• Arbyn M, Autier P, Ferlay J. Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004. Ann. Oncol.18(8), 1423–1425 (2007).
   PubMed Web of Science ®Google Scholar
• Arbyn M, Primic-Zakelj M, Raifu AO et al. The burden of cervical cancer in south-east Europe at the beginning of the 21st Century. Coll. Antropol.31(Suppl. 2), 7–10 (2007).
   PubMedGoogle Scholar
• WHO. Comprehensive Cervical Cancer Control: a Guide to Essential Practice. WHO, Geneva, Switzerland (2006).
   Google Scholar
• von Karsa L, Anttila A, Ronco G et al. Cancer screening in the European Union. In: Report on the Implementation of the Council Recommendation on Cancer Screening (First Report). International Agency for Research on Cancer, European Communities, Brussels, Belgium (2008).
   Google Scholar
• Anttila A, von Karsa L, Aasmaa A et al.Cervical cancer screening policies and coverage in Europe. Eur. J. Cancer DOI:1 0.1016/j.ejca.2009.07.020 (2009) (Epub ahead of print).
   Google Scholar
• Arbyn M, Rebolj M, De Kok IM et al. The challenges of organising cervical screening programmes in the 15 old member states of the European Union. Eur. J. Cancer DOI: 10.1016/j.ejca.2009.07.016 (2009) (Epub ahead of print).
   Google Scholar
• Nicula FA, Anttila A, Neamtiu L et al.Challenges in starting organised screening programmes for cervical cancer in the new member states of the European Union. Eur. J. Cancer DOI: 10.1016/j.ejca.2009.07.025 (2009) (Epub ahead of print).
   Google Scholar
• European Commission. European Guidelines for Quality Assurance in Cervical Cancer Screening (Second Edition). Arbyn M, Anttila A, Jordan J et al. (Eds). Office for Official Publications of the European Communities, Luxembourg, Luxembourg (2008).
   Google Scholar
• Lévy-Bruhl D, Bousquet V, King LA et al. The current state of introduction of HPV vaccination into national immunisation schedules in Europe: results of the VENICE 2008 Survey. Eur. J. Cancer DOI: 10.1016/j.ejca.2009.07.023 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am. J. Epidemiol.141(7), 680–689 (1995).
   PubMed Web of Science ®Google Scholar
• Karnon J, Peters J, Platt J et al. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol. Assess.8(20), iii, 1–78 (2004)
   Google Scholar
• Kitchener HC, Almonte M, Thomson C et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol.10(7), 672–682 (2009).
   PubMed Web of Science ®Google Scholar
• Arbyn M, Bergeron C, Klinkhamer P et al. Liquid compared with conventional cervical cytology. Obstet. Gynecol.111(1), 167–177 (2008).
   PubMedGoogle Scholar
• Arbyn M, Buntinx F, Van Ranst M et al. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J. Natl Cancer Inst.96(4), 280–293 (2004).
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sasieni P, Davies P et al. A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions. Br. J. Cancer83(5), 561–565 (2000).
   PubMedGoogle Scholar
• Arbyn M, Martin-Hirsch P, Buntinx F et al. Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate.J. Cell Mol. Med.13(4), 648–659 (2009).
   PubMed Web of Science ®Google Scholar
• Cuzick J, Szarewski A, Cubie Het al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet362(9399), 1871–1876 (2003).
   PubMed Web of Science ®Google Scholar
• Cuzick J, Clavel C, Petry KU et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer119(5), 1095–1101 (2006).
   PubMed Web of Science ®Google Scholar
• Grce M, Davies P. Human papillomavirus testing for primary cervical cancer screening. Expert Rev. Mol. Diagn.8(5), 599–605 (2008).
   PubMed Web of Science ®Google Scholar
• Bulkmans NW, Berkhof J, Rozendaal L et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet370(9601), 1764–1772 (2007).
   PubMed Web of Science ®Google Scholar
• Cuzick J, Arbyn M, Sankaranarayanan Ret al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine26(Suppl. 10), K29–K41 (2008).
   PubMed Web of Science ®Google Scholar
• Qiao YL, Sellors JW, Eder PS et al.A new HPV-DNA test for cervical-cancer screening in developing regions: a crosssectional study of clinical accuracy in rural China. Lancet Oncol.9(10), 929–936 (2008).
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Nene BM, Shastri SS et al. HPV screening for cervical cancer in rural India. N. Engl. J. Med.360(14), 1385–1394 (2009).
   PubMed Web of Science ®Google Scholar
• Carozzi F, Confortini M, Dalla Palma P et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol.9(10), 937–945 (2008).
   PubMed Web of Science ®Google Scholar
• FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med.356(19), 1915–1927 (2007).
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmerón J et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet374(9686), 301–314 (2009).
   PubMed Web of Science ®Google Scholar
• Brown DR, Kjaer SK, Sigurdsson K et al.The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J. Infect. Dis.199(7), 926–935 (2009).
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Kjaer SK, Sigurdsson K et al.The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years. J. Infect. Dis.199(7), 936–944 (2009).
   PubMed Web of Science ®Google Scholar
• Clifford GM, Smith JS, Plummer M et al.Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer88(1), 63–73 (2003).
   PubMed Web of Science ®Google Scholar
• Franco EL, Cuzick J, Hildesheim A, de Sanjosé S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine24(Suppl. 3), 171–177 (2006).
   PubMedGoogle Scholar
• Gao S. Development of HPV and HEV vaccines. Presented at: 8th Developing Countries Vaccine Manufacturers’ Network (DCVMN) Annual General Meeting. Rio de Janiero, Brazil, 12 November 2007.
   Google Scholar